ClinicalTrials.gg
CompletedNCT07801742Updated Sep 3, 2026

EFFECT OF ZOLPIDEM ON SLEEP QUALITY AND OPIOID CONSUMPTION FOLLOWING PRIMARY TOTAL KNEE ARTHROPLASTY: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

A Phase 4 interventional study of Zolpidem 10 mg tablets and Avocado-soybean unsaponifiables 300 mg in Postoperative Pain Management in Total Knee Arthroplasty, sponsored by Sanatorio Allende. Completed at 1 site in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Sanatorio Allende · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Aug 2025, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders — 2 open to participants now, 2 under way, 1 of them phase 3. Zolpidem · Sleep Initiation and Maintenance Disorders.

Enrollment
28th of 40
54 · median 108
Started
2025
the only one that year
Phase 4
19 of 40
1 open now
Registered
40th of 40
by date

Among the 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders, this one is the 28th largest by enrollment, is the only one that started in 2025, is one of 19 in phase 4, and was the 40th registered.

Sleep Initiation and Maintenance Disorders

2,732 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 733 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

2 of the 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About zolpidem

Zolpidem: first FDA approval 1992 (AMBIEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 392 Sleep Initiation and Maintenance Disorders studies recruiting now, 155 (40%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 110 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

This clinical trial evaluated whether zolpidem could improve sleep quality and postoperative recovery in patients undergoing total joint arthroplasty. Participants were randomly assigned to receive either zolpidem 10 mg or a placebo for 14 nights, beginning after hospital discharge. Neither the participants nor their physicians knew which treatment was assigned. The study assessed sleep quality and duration, postoperative pain, use of pain medications, functional recovery, satisfaction, and adverse events. The study hypothesis was that improving sleep with zolpidem would lead to better sleep and potentially improve pain control and recovery after surgery compared with placebo.

03

Conditions studied

  • Postoperative Pain Management in Total Knee Arthroplasty

Keywords

  • Zolpidem
  • Sleep quality
  • Postoperative pain
  • Total knee arthroplasty
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Undergoing primary total knee arthroplasty (TKA).
  • Ability to understand the study procedures.
  • Ability to provide written .
  • Ability to complete the postoperative questionnaires.

Exclusion criteria

Exclusion Criteria:

  • History of to zolpidem or other hypnotic agents.
  • Revision total knee arthroplasty.
  • Arthroplasty performed for fracture.
  • Preoperative use of sleep medications.
  • Obstructive sleep apnea.
  • Severe respiratory insufficiency.
  • Severe hepatic disease.
  • Cognitive impairment preventing reliable assessment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants assigned to this arm received placebo orally once nightly for 14 consecutive nights after total knee arthroplasty.

    Drug: Avocado-soybean unsaponifiables 300 mg

  • Experimental
    Zolpidem

    Participants assigned to this arm received zolpidem 10 mg orally once nightly for 14 consecutive nights after total knee arthroplasty.

    Drug: Zolpidem 10 mg tablets

Interventions

  • DrugZolpidemStudies of ZolpidemZolpidem pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Zolpidem 10 mg was administered orally once nightly for 14 consecutive nights following total knee arthroplasty.

  • DrugAvocado-soybean unsaponifiables 300 mg

    Avocado-soybean unsaponifiables (Prontal) 300 mg were administered orally once nightly for 14 consecutive nights following total knee arthroplasty.

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Intensity Assessed Using the Numeric Rating Scale

    Postoperative pain intensity was assessed using an 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicated greater pain intensity.

    Time frame: Postoperative days 7 and 14

  2. Postoperative Sleep Quality Assessed Using a 5-Point Likert Scale

    Overall postoperative sleep quality was assessed using a study-specific question rated on a 5-point Likert scale. The question was selected with reference to conceptual domains of the Pittsburgh Sleep Quality Index (PSQI); however, the PSQI itself was not administered or scored. Higher scores indicated better perceived sleep quality.

    Time frame: Postoperative days 7 and 14

Secondary outcomes

  1. Pain-Related Interference With Sleep

    Pain-related interference with sleep was assessed using a study-specific question evaluating whether postoperative pain interfered with the patient's sleep.

    Time frame: Postoperative days 7 and 14

  2. Postoperative Analgesic Consumption

    Postoperative analgesic consumption was assessed using a study-specific questionnaire recording the patient's use of analgesic medication during the postoperative period.

    Time frame: Postoperative days 7 and 14

  3. Use of Rescue Tramadol

    Use of rescue tramadol for postoperative pain management was recorded using a study-specific questionnaire.

    Time frame: Postoperative days 7 and 14

  4. Participation in Postoperative Rehabilitation

    Participation in postoperative rehabilitation was assessed using a study-specific questionnaire recording whether the patient was participating in rehabilitation activities.

    Time frame: Postoperative days 7 and 14

  5. Daily Duration of Postoperative Rehabilitation

    The duration of postoperative rehabilitation was assessed by patient report and recorded as the average number of minutes of rehabilitation performed per day.

    Time frame: Postoperative days 7 and 14

  6. Self-Reported Mobility Compared With Hospital Discharge

    Postoperative mobility was assessed using a study-specific question in which patients reported their mobility relative to their mobility at the time of hospital discharge.

    Time frame: Postoperative days 7 and 14

  7. Patient Satisfaction With Sleep Quality Assessed Using a 5-Point Likert Scale

    Patient satisfaction with postoperative sleep quality was assessed using a study-specific 5-point Likert scale. Higher scores indicated greater satisfaction with sleep quality.

    Time frame: Postoperative days 7 and 14

  8. Patient Satisfaction With Pain Management Assessed Using a 5-Point Likert Scale

    Patient satisfaction with postoperative pain management was assessed using a study-specific 5-point Likert scale. Higher scores indicated greater satisfaction with pain management.

    Time frame: Postoperative days 7 and 14

  9. Number of Participants With Treatment-Related Adverse Events

    Treatment-related adverse events were assessed using study-specific questions. Recorded events included daytime somnolence, falls, confusion, and other patient-reported complications.

    Time frame: Through postoperative day 14

  10. Average Sleep Duration

    Average postoperative sleep duration was assessed by patient self-report using a study-specific question and recorded as the average number of hours slept.

    Time frame: Postoperative days 7 and 14

  11. Nocturnal Awakenings

    Nocturnal awakenings during the postoperative period were assessed using a study-specific question

    Time frame: Postoperative days 7 and 14

07

Study locations

1 site
  • Sanatorio Allende
    Córdoba, Córdoba Province 5000, Argentina
08

References and documents

Publications

  • O'Hagan ET, Hubscher M, Miller CB, Gordon CJ, Gustin S, Briggs N, McAuley JH. Zolpidem reduces pain intensity postoperatively: a systematic review and meta-analysis of the effect of hypnotic medicines on post-operative pain intensity. Syst Rev. 2020 Sep 3;9(1):206. doi: 10.1186/s13643-020-01458-8. PubMed 32883342 ↗
  • Krenk L, Jennum P, Kehlet H. Postoperative sleep disturbances after zolpidem treatment in fast-track hip and knee replacement. J Clin Sleep Med. 2014 Mar 15;10(3):321-6. doi: 10.5664/jcsm.3540. PubMed 24634631 ↗

Individual participant data

Plan to share: Yes — Deidentified individual participant data (IPD) that underlie the results reported in the published article will be made available. The shared dataset may include baseline demographic and clinical characteristics, treatment allocation, postoperative sleep and pain assessments, analgesic use, rehabilitation and mobility outcomes, patient satisfaction, and reported adverse events. All data will be deidentified prior to sharing to protect participant confidentiality. No personally identifiable information will be shared.

Supporting information: Study protocol

Time frame: Data will be available beginning 6 months after publication of the study results and will remain available for 5 years.

Access criteria: Deidentified individual participant data and supporting information will be made available to qualified researchers upon reasonable request to the corresponding author. Requests should include a brief research proposal describing the purpose of the analysis and the data requested. Access will be granted following review and approval by the study investigators, provided that the proposed use is scientifically appropriate and consistent with participant confidentiality and applicable ethical requirements.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Jun 2026, 10 months.

Of 52 non-industry phase 4 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 59. This study's 10 months is below that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Sep 3, 2026
StartActual
Aug 5, 2025
Primary completionActual
Jun 9, 2026
CompletionActual
Jun 9, 2026
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07801742
Lead sponsor
Sanatorio Allende
Responsible party
Juan pablo Melo (Staff Orthopedic Surgeon, Sanatorio Allende) — Principal investigator
First posted
Sep 3, 2026
Start date
Aug 5, 2025
Primary completion
Jun 9, 2026
Completion
Jun 9, 2026
Last update
Sep 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zolpidem

Start the discussion